Cingulate is a biopharmaceutical company developing CTx-1301, a once-daily, three-release tablet of dexmethylphenidate for ADHD; FDA has not approved it and asked for more manufacturing information.
Cingulate's case rests on CTx-1301, a dexmethylphenidate tablet for ADHD built so one morning dose lasts the whole day, which completed Phase 3. On June 1 FDA issued a Complete Response Letter asking for more manufacturing (CMC) information, with no concerns about clinical safety or efficacy. Cingulate has not given a resubmission date, cash of $28.4 million should last into mid-2027, and a launch would face many generic stimulants.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: NDA resubmitted with complete CMC answers
Does Cingulate resubmit soon with a complete CMC package that FDA accepts for a short review?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Cingulate is completing manufacturing work after FDA's June 1 Complete Response Letter for its ADHD drug CTx-1301, which raised no clinical concerns; no resubmission date yet
CTx-1301 faces CMC-only CRL resubmission; thesis hinges on whether FDA accepts manufacturing responses without raising new clinical concerns
CTx-1301's ADHD approval hangs on whether FDA accepts manufacturing responses before or at the May 31, 2026 PDUFA date
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
9 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.